AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01587664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NewBreez ILP
Description: NewBreez ILP implantation
Study NCT03878810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: A video game-based physical activity training applied using a commercial game console.
Study NCT01744028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
Study NCT01744028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
Study NCT00105638 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational program, by telephone
Study NCT03699943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CaverStem
Study NCT02166008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repamipide
Study NCT02166008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil, 16 mg, capsule, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan matching placebo
Description: Candesartan matching placebo, capsule, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
Study NCT02047019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
Study NCT03291574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
Study NCT03291574 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
Study NCT03150056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 will be administered.
Study NCT03150056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered.
Study NCT03150056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered.
Study NCT03150056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as a concomitant medication in combination with abiraterone
Study NCT01201629 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: t DC stimulation
Description: tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
Study NCT01201629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t DC stimulation
Description: tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
Study NCT01201629 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCStimulation
Description: 1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
Study NCT01201629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCStimulation
Description: 1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
Study NCT03104634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate dihydrate
Description: Cross-over design with washout interval. Randomized order of active and placebo arm
Study NCT03104634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and delivery device matched to active intervention
Study NCT02952924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
Study NCT02952924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
Study NCT02952924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
Study NCT02952924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.
Study NCT00281983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00281983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT03298126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TR BAND removal protocol
Description: To assess radial artery patency after specific protocol used as already described in previous section.
Study NCT03095040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 combined with everolimus
Description: CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
Study NCT03095040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
Study NCT03095040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
Study NCT00921492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency electro-acupuncture (EA)
Description: 2 Hz EA during 30 minutes, twice a week, 14 weeks.
Study NCT00921492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meeting a therapist - attention control
Description: Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
Study NCT02158299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avitene
Study NCT02915705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Phosphate Supplement
Description: oral tablet; oral solution; oral powder
Study NCT02915705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active vitamin D
Description: tablet, oral solution
Study NCT02158299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapylin
Study NCT02158299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: axillary drainage
Study NCT02158299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: axillary drainage
Study NCT04044040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom screening with Targeted Early Palliative care (STEP)
Description: The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
Study NCT02158299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reexamine
Study NCT02158299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reexamine
Study NCT04021953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: People Like Us Online Video Series Intervention
Description: People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men.
Study NCT04021953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Health Pamphlet (Standard of Care)
Description: The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
Study NCT00281983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00281983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00281983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT04021953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Pamphlet (Standard of Care)
Description: The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
Study NCT01581281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
Study NCT01581281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
Study NCT01581281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
Study NCT01964170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: subcutaneous
Study NCT01819233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral dietary intervention
Description: Receive caloric restricted dietary intervention
Study NCT01819233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic conventional surgery
Description: Undergo definitive lumpectomy
Study NCT01819233 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo radiation therapy
Study NCT01819233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Description: Receive dietary counseling
Study NCT01819233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT02982681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
Study NCT02982681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bioactive Glass
Description: The control site were packed with the bioactive glass graft alone
Study NCT02283684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight laser PVP
Description: Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
Study NCT02283684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar TUVP
Description: Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
Study NCT03690843 — intervention group
Intervention type: OTHER
Intervention: Test Battery
Description: All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
Study NCT02840539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
Description: Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles
Study NCT02838797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RQ-00000010
Description: orally administered serotonin 4 receptor partial agonist
Study NCT02838797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral acetate buffer
Study NCT04152837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist
Study NCT03917446 — intervention group
Intervention type: DRUG
Intervention: Propofol bolus
Description: Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
Study NCT05251896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma-free procedure
Description: Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
Study NCT01905527 — intervention group
Intervention type: OTHER
Intervention: Standard Services of Group A (Group A1)
Description: Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
Study NCT01905527 — intervention group
Intervention type: OTHER
Intervention: Customized Services of Group A (Group A2)
Description: In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
Study NCT01905527 — intervention group
Intervention type: OTHER
Intervention: Group B
Description: Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
Study NCT00880113 — intervention group
Intervention type: PROCEDURE
Intervention: Non-contrast CT, CT-perfusion and CT-angiography
Description: Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
Study NCT01609296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral™ Drug Eluting Balloon
Description: IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
Study NCT04040140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APA Treatment
Description: Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
Study NCT04325568 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PsyGist and Clinician Manual
Description: This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
Study NCT04446338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody Test
Description: Presence and Titer of Anti-Sars-CoV-2 Antbodies
Study NCT02641418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supervised exercise programme
Description: supervised exercise programme
Study NCT03601598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200mg iv every 2 weeks
Study NCT01964170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: subcutaneous
Study NCT04223180 — intervention group
Intervention type: DEVICE
Intervention: Robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study NCT01558622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexketoprofen trometamol
Description: 50mg intravenous infusion
Study NCT01558622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tramadol hydrochloride
Description: 100mg intravenous infusion
Study NCT01558622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pethidine hydrochloride
Description: 50mg intravenous infusion
Study NCT01558622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexketoprofen trometamol + tramadol hydrochloride
Description: intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
Study NCT01558622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexketoprofen trometamol + pethidine hydrochloride
Description: intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
Study NCT01558622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin c
Description: 500mg intravenous infusion
Study NCT03066336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia LunulaLaser
Description: Active Low Level Laser Light Therapy
Study NCT03601598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
Study NCT02609815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin
Description: zemimet-SR 50/1000 mg x 1 tablet
Study NCT02609815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride/metformin
Description: amaryl-Mex 1/500 mg x 2 tablets